Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Multiple Myeloma 75Recurrence 11Neoplasms, Plasma Cell 6Waldenstrom Macroglobulinemia 2Neoplasms 2Plasmacytoma 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Leukemia, Plasma Cell 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Rituximab 16zanubrutinib 12ibrutinib 9venetoclax 8Cyclophosphamide 8pirtobrutinib 5fludarabine phosphate 5Whole-Body Irradiation 5Sirolimus 5Mycophenolic Acid 5Bendamustine Hydrochloride 5acalabrutinib 4Peripheral Blood Stem Cell Transplantation 4Dexamethasone 4ixazomib 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Cyclosporine 3Bortezomib 3Biopsy 3fludarabine 2carfilzomib 2Tacrolimus 2Prednisone 2Melphalan 2Etoposide 2Cyclosporins 2Calcium Dobesilate 2CT-P10 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × carfilzomib × 1 year × Clear all
NCT04263480 2026-05-12

CZAR-1

University of Ulm

Phase 2 Active not recruiting
99 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Neoplasms

NCT01813227 2026-04-03

A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531

Hackensack Meridian Health

Phase 2 Completed
7 enrolled 10 charts
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡